EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A Clinical and Molecular Comparative Analysis of KRAS Exon 2 and KRAS Non-Exon 2 Mutated Colorectal Cancer

Doga Kahramangil Baytar, Paola Zinser-Peniche, Shuaichao Wang, Yu Jen Alexander Jan, Ashley McFarquhar, Aatur Singhi iD, Anwaar Saeed, Ibrahim Halil Sahin

Cancers · 05.07.2026 · 18 (13) · 2158

DOI: 10.3390/cancers18132158 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancers, online erschienen am 05.07.2026. Verfasst von Doga Kahramangil Baytar und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of Pittsburgh Medical Center (UPMC), Pittsburgh, PA 15213, USA. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Mutations in the KRAS oncogene occur in approximately 40% of colorectal cancers, predominantly within exon 2. Non-exon 2 mutations are less common and remain poorly characterized in terms of their clinical and biological significance. Systemic inflammatory markers are well-established prognostic indicators in colorectal cancer, yet whether their prognostic value differs across KRAS mutation subtypes has yet to be defined. We aimed to characterize and compare the clinicopathological and inflammatory profiles of patients with exon 2 versus non-exon 2 KRAS-mutated colorectal cancer and evaluate their prognostic implications.

Methods

This retrospective cohort study analyzed 272 patients with microsatellite stable metastatic colorectal cancer with KRAS mutations, comprising 236 exon 2 and 36 non-exon 2 cases. Clinical, molecular, and laboratory data, including baseline systemic inflammatory markers, were extracted from electronic medical records. Survival outcomes and the prognostic impact of these variables were evaluated with Kaplan-Meier curves and univariable and multivariable Cox proportional hazards regression analyses.

Results

Non-exon 2 mutations were significantly more frequent in female patients (64% vs. 45%, p = 0.048) and in left-sided primary tumors (83% vs. 64%, p = 0.035). Median overall survival was 45.7 months for the non-exon 2 group compared to 32.4 months for the exon 2 cohort; KRAS mutation subtype was not significantly associated with overall survival on univariable or multivariable analysis (univariable HR 1.36, 95% CI 0.85–2.16, p = 0.2; multivariable HR 1.376, 95% CI 0.794–2.383, p = 0.255). Systemic inflammation demonstrated distinct prognostic value, with elevated white blood cells, absolute neutrophil count, platelets, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and low albumin levels demonstrating association with worse overall survival in the exon 2 cohort. Conversely, only an elevated neutrophil-to-lymphocyte ratio predicted worse survival in the non-exon 2 group.

Conclusions

KRAS exon 2 and non-exon 2 mutated metastatic colorectal cancers exhibit distinct clinical and inflammatory characteristics. Systemic inflammation exerts a significantly greater prognostic impact in exon 2 disease. As the therapeutic landscape for KRAS-mutated CRC continues to evolve, these findings hold promise for informing KRAS mutation-specific approaches to patient stratification and treatment planning.

Schlagwörter

Stichwörter der Autor:innen

KRAS exon 2KRAS mutationKRAS mutation subtypesKRAS non-exon 2colorectal cancerinflammatory markersneutrophil-to-lymphocyte ratio

Autor:innen und Institutionen

  • Department of Medicine, University of Pittsburgh Medical Center (UPMC), Pittsburgh, PA 15213, USA.
  • UPMC Hillman Cancer Center, Pittsburgh, PA 15213, USA.
  • Division of Hematology & Oncology, University of Pittsburgh Medical Center (UPMC), Pittsburgh, PA 15213, USA.
  • Department of Pathology, University of Pittsburgh Medical Center (UPMC), Pittsburgh, PA 15213, USA.
  • Division of Hematology & Oncology, University of Michigan Medical School, Ann Arbor, MI 48109, USA.

ORCID-Profile: Aatur Singhi

Zitieren

APA

Kahramangil Baytar, D., Zinser-Peniche, P., Wang, S., Jan, Y. J. A., McFarquhar, A., Singhi, A., Saeed, A., & Sahin, I. H. (2026). A Clinical and Molecular Comparative Analysis of KRAS Exon 2 and KRAS Non-Exon 2 Mutated Colorectal Cancer. Cancers, 18(13), 2158. https://doi.org/10.3390/cancers18132158

Vancouver

Kahramangil Baytar D, Zinser-Peniche P, Wang S, Jan YJA, McFarquhar A, Singhi A, et al. A Clinical and Molecular Comparative Analysis of KRAS Exon 2 and KRAS Non-Exon 2 Mutated Colorectal Cancer. Cancers. 2026;18(13):2158. doi:10.3390/cancers18132158

BibTeX
@article{KahramangilBaytar2026,
  author = {Kahramangil Baytar, Doga and Zinser-Peniche, Paola and Wang, Shuaichao and Jan, Yu Jen Alexander and McFarquhar, Ashley and Singhi, Aatur and Saeed, Anwaar and Sahin, Ibrahim Halil},
  title = {A Clinical and Molecular Comparative Analysis of KRAS Exon 2 and KRAS Non-Exon 2 Mutated Colorectal Cancer},
  journal = {Cancers},
  year = {2026},
  volume = {18},
  number = {13},
  pages = {2158},
  doi = {10.3390/cancers18132158}
}
Kostenlos starten →